BRPI0411872A - composição farmacêutica - Google Patents
composição farmacêuticaInfo
- Publication number
- BRPI0411872A BRPI0411872A BRPI0411872-3A BRPI0411872A BRPI0411872A BR PI0411872 A BRPI0411872 A BR PI0411872A BR PI0411872 A BRPI0411872 A BR PI0411872A BR PI0411872 A BRPI0411872 A BR PI0411872A
- Authority
- BR
- Brazil
- Prior art keywords
- poly
- alkyl
- pharmaceutical composition
- present
- supramolecular assemblies
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 230000000712 assembly Effects 0.000 abstract 2
- 238000000429 assembly Methods 0.000 abstract 2
- 239000000693 micelle Substances 0.000 abstract 2
- -1 poly(ethylene oxide) Polymers 0.000 abstract 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 abstract 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 abstract 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 229920001400 block copolymer Polymers 0.000 abstract 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000007613 environmental effect Effects 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
- C08L71/02—Polyalkylene oxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Polymers & Plastics (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cephalosporin Compounds (AREA)
Abstract
"COMPOSIçãO FARMACêUTICA". A invenção atual refere-se a uma composição farmacêutica de um agente biologicamente ativo e um copolímero em bloco composto de um poli (óxido de etileno) que forma um segmento hidrófilo e um poli(butil(alquil)acrilato-co-(alquil)ácido acrílico) que é capaz de formar conjuntos ou micelas supramoleculares sob condições favoráveis. Os conjuntos ou micelas supra- moleculares formados a partir dos referidos polímeros, se associam ou se dissociam reversivelmente com as alterações no pH ambiental. As composições farmacêuticas da invenção atual contêm drogas hidrofóbicas, cátions ou compostos policatiónicos, que podem ser administrados para o corpo pela rota oral ou por outras rotas de administração.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/607,446 US7094810B2 (en) | 2001-06-08 | 2003-06-25 | pH-sensitive block copolymers for pharmaceutical compositions |
PCT/CA2004/000561 WO2004112757A1 (en) | 2003-06-25 | 2004-04-14 | Pharmaceutical compositions comprising ph-sensitive block copolymers and a hydrophobic drug |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0411872A true BRPI0411872A (pt) | 2006-08-08 |
Family
ID=33540273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0411872-3A BRPI0411872A (pt) | 2003-06-25 | 2004-04-14 | composição farmacêutica |
Country Status (16)
Country | Link |
---|---|
US (1) | US7094810B2 (pt) |
EP (1) | EP1638539B1 (pt) |
JP (1) | JP4619357B2 (pt) |
AT (1) | ATE418970T1 (pt) |
AU (1) | AU2004248863B2 (pt) |
BR (1) | BRPI0411872A (pt) |
CA (1) | CA2530736C (pt) |
CY (1) | CY1110264T1 (pt) |
DE (1) | DE602004018772D1 (pt) |
DK (1) | DK1638539T3 (pt) |
ES (1) | ES2323701T3 (pt) |
MX (1) | MXPA05014017A (pt) |
PL (1) | PL1638539T3 (pt) |
PT (1) | PT1638539E (pt) |
SI (1) | SI1638539T1 (pt) |
WO (1) | WO2004112757A1 (pt) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003523544A (ja) * | 2000-02-17 | 2003-08-05 | レックスマーク・インターナショナル・インコーポレーテツド | 導電性駆動ハブを備えたトナーカートリッジ |
US6939564B2 (en) * | 2001-06-08 | 2005-09-06 | Labopharm, Inc. | Water-soluble stabilized self-assembled polyelectrolytes |
WO2005079856A1 (en) * | 2004-02-23 | 2005-09-01 | The University Of British Columbia | Drug delivery compositions comprising hydrophobic polymers and amphipathic molecules |
US20060198891A1 (en) * | 2004-11-29 | 2006-09-07 | Francois Ravenelle | Solid formulations of liquid biologically active agents |
US20090074872A1 (en) * | 2006-06-26 | 2009-03-19 | Mutual Pharmaceutical Company, Inc. | Active Agent Formulations, Methods of Making, and Methods of Use |
CN101505733A (zh) * | 2006-06-26 | 2009-08-12 | 共有药物有限公司 | 活性剂制剂及其制备和应用方法 |
JP2010504318A (ja) * | 2006-09-22 | 2010-02-12 | ラボファーム インコーポレイテッド | pH標的化薬剤送達のための組成物及び方法 |
US8685417B2 (en) * | 2006-12-20 | 2014-04-01 | Arkema, Inc. | Polymer encapsulation and/or binding |
WO2008128292A1 (en) * | 2007-04-20 | 2008-10-30 | University Of South Australia | Nanoparticle-coated capsule formulation for dermal drug delivery |
TW200918099A (en) * | 2007-09-14 | 2009-05-01 | Nitto Denko Corp | Drug carriers |
FR2922452B1 (fr) * | 2007-10-19 | 2010-01-22 | Coatex Sas | Formulations de composes organoplatiniques en presence de polymeres associatifs, produits obtenus et leurs utilisations |
TWI388591B (zh) * | 2008-03-28 | 2013-03-11 | Ind Tech Res Inst | 溫度敏感性材料 |
US8778400B2 (en) * | 2008-04-21 | 2014-07-15 | University Of South Australia | Nanoparticle-stabilized capsule formulation for treatment of inflammation |
JP2011520901A (ja) * | 2008-05-13 | 2011-07-21 | ユニヴァーシティ オブ ワシントン | 治療剤の細胞内送達のためのミセル |
CA2724455A1 (en) * | 2008-05-13 | 2009-11-19 | University Of Washington | Polymeric carrier |
BRPI0911989A2 (pt) * | 2008-05-13 | 2015-10-20 | Phaserx Inc | uniões micélicas |
JP5911723B2 (ja) | 2008-05-13 | 2016-04-27 | ユニヴァーシティ オブ ワシントン | 細胞内に送達するためのジブロックコポリマーおよびそのポリヌクレオチド複合体 |
WO2009140423A2 (en) * | 2008-05-13 | 2009-11-19 | University Of Washington | Targeted polymer bioconjugates |
JP5663472B2 (ja) * | 2008-05-16 | 2015-02-04 | ザ・ユニバーシティ・オブ・シドニー | 投与可能組成物 |
CA2635187A1 (en) * | 2008-06-05 | 2009-12-05 | The Royal Institution For The Advancement Of Learning/Mcgill University | Oligonucleotide duplexes and uses thereof |
PL2305275T3 (pl) * | 2008-06-24 | 2013-12-31 | Nanocarrier Co Ltd | Ciekła kompozycja zawierająca koordynacyjny związek cisplatyny |
EP2331069A4 (en) | 2008-08-22 | 2011-10-26 | Univ Washington | HETEROGENEOUS POLYMER MICELLES FOR INTRACELLULAR DELIVERY |
CA2742880A1 (en) | 2008-11-06 | 2010-05-14 | University Of Washington | Multiblock copolymers |
US8822213B2 (en) | 2008-11-06 | 2014-09-02 | University Of Washington | Bispecific intracellular delivery vehicles |
US9593169B2 (en) | 2008-12-08 | 2017-03-14 | University Of Washington | Omega-functionalized polymers, junction-functionalized block copolymers, polymer bioconjugates, and radical chain extension polymerization |
US20100159010A1 (en) * | 2008-12-24 | 2010-06-24 | Mutual Pharmaceutical Company, Inc. | Active Agent Formulations, Methods of Making, and Methods of Use |
TWI374903B (en) * | 2008-12-31 | 2012-10-21 | Ind Tech Res Inst | Biodegradable copolymer hydrogel materials |
WO2011062965A2 (en) | 2009-11-18 | 2011-05-26 | University Of Washington Through Its Center For Commercialization | Targeting monomers and polymers having targeting blocks |
WO2015017519A1 (en) | 2013-07-30 | 2015-02-05 | Phaserx, Inc. | Block copolymers and their conjugates or complexes with oligonucleotides |
US11219634B2 (en) | 2015-01-21 | 2022-01-11 | Genevant Sciences Gmbh | Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells |
US10407437B2 (en) | 2016-03-08 | 2019-09-10 | Los Gatos Pharmaceuticals, Inc. | Camptothecin derivatives and uses thereof |
EP3426301A4 (en) | 2016-03-08 | 2019-11-06 | Los Gatos Pharmaceuticals, Inc. | VERBUNDNANOPARTICLES AND USES THEREOF |
CN106432647B (zh) * | 2016-09-26 | 2018-10-30 | 华南理工大学 | 基于叔氨基的pH响应嵌段聚合物及其混合胶束与应用 |
EP3562510A4 (en) | 2016-12-30 | 2021-01-06 | Genevant Sciences GmbH | BRANCHED PEG MOLECULES AND ASSOCIATED COMPOSITIONS AND PROCEDURES |
WO2019032975A1 (en) * | 2017-08-10 | 2019-02-14 | Mec Device Pharma International Llc | ANTI-ABUSE MEDICINAL FORMULATIONS |
CN114377144B (zh) * | 2022-01-28 | 2024-10-29 | 南通大学 | pH/活性氧双重响应性超分子聚肽前药纳米粒子 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1411843A (en) * | 1973-02-28 | 1975-10-29 | Univ Strathclyde | Method of modifying the properties of a polymer |
JPS5767860A (en) * | 1980-10-15 | 1982-04-24 | Fuji Photo Film Co Ltd | Material for multilayer analysis |
JP2517760B2 (ja) * | 1989-05-11 | 1996-07-24 | 新技術事業団 | 水溶性高分子化医薬製剤 |
KR940003548U (ko) * | 1992-08-14 | 1994-02-21 | 김형술 | 세탁물 건조기 |
US5840319A (en) * | 1992-10-08 | 1998-11-24 | Alakhov; Valery Yu | Biological agent compositions |
EP0639592A1 (en) * | 1993-08-18 | 1995-02-22 | Nippon Shokubai Co., Ltd. | Water-soluble graft polymers and production process thereof |
JP3631755B2 (ja) * | 1994-03-23 | 2005-03-23 | 明治製菓株式会社 | ポリオキシエチレン含有脂質二本鎖誘導体 |
US5620850A (en) * | 1994-09-26 | 1997-04-15 | President And Fellows Of Harvard College | Molecular recognition at surfaces derivatized with self-assembled monolayers |
US5997861A (en) | 1994-10-31 | 1999-12-07 | Burstein Laboratories, Inc. | Antiviral supramolecules containing target-binding molecules and therapeutic molecules bound to spectrin |
US6221959B1 (en) * | 1994-11-18 | 2001-04-24 | Supratek Pharma, Inc. | Polynucleotide compositions |
US5656611A (en) * | 1994-11-18 | 1997-08-12 | Supratek Pharma Inc. | Polynucleotide compositions |
AU4690596A (en) | 1994-12-30 | 1996-07-24 | Chiron Viagene, Inc. | Nucleic acid condensing agents with reduced immunogenicity |
US5492996A (en) * | 1995-02-21 | 1996-02-20 | The United States Of America As Represented By The Secretary Of The Air Force | Alcohol soluble benzazole polymers |
DE69624475T2 (de) * | 1995-04-19 | 2003-05-28 | Kazunori Kataoka | Heterotelechelische blockcopolymere und verfahren zu deren herstellung |
US5908777A (en) * | 1995-06-23 | 1999-06-01 | University Of Pittsburgh | Lipidic vector for nucleic acid delivery |
US5929177A (en) * | 1995-08-10 | 1999-07-27 | Kazunori Kataoka | Block polymer having functional groups at both ends |
US5770627A (en) * | 1995-08-16 | 1998-06-23 | University Of Washington | Hydrophobically-modified bioadhesive polyelectrolytes and methods relating thereto |
US5702717A (en) * | 1995-10-25 | 1997-12-30 | Macromed, Inc. | Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers |
EP0894043B1 (en) | 1996-03-15 | 2001-10-31 | President And Fellows Of Harvard College | Method of forming articles and patterning surfaces via capillary micromolding |
US5955509A (en) * | 1996-05-01 | 1999-09-21 | Board Of Regents, The University Of Texas System | pH dependent polymer micelles |
CA2258744A1 (en) * | 1996-06-27 | 1997-12-31 | G.D. Searle And Co. | Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications |
GB9623051D0 (en) | 1996-11-06 | 1997-01-08 | Schacht Etienne H | Delivery of DNA to target cells in biological systems |
US6235309B1 (en) | 1997-02-28 | 2001-05-22 | The Regents Of The University Of California | Inhibition of cell-cell binding by lipid assemblies |
EP0963758A3 (en) | 1998-05-07 | 2000-03-22 | Universiteit Gent | Synthetic polyaminoacid complexes for delivery of nucleic acids to target cells |
US5939453A (en) * | 1998-06-04 | 1999-08-17 | Advanced Polymer Systems, Inc. | PEG-POE, PEG-POE-PEG, and POE-PEG-POE block copolymers |
AU5100899A (en) * | 1998-07-13 | 2000-02-01 | Expression Genetics, Inc. | Polyester analogue of poly-l-lysine as a soluble, biodegradable gene delivery carrier |
DE19919785A1 (de) * | 1999-04-30 | 2000-12-07 | Wella Ag | Haarbehandlungsmittel mit Polymeren aus ungesättigten Sacchariden, ungesättigten Saccharidsäuren oder deren Derivaten |
DE10008895A1 (de) * | 2000-02-25 | 2001-08-30 | Beiersdorf Ag | Stabilisierung oxidations- und/oder UV-empfindlicher Wirkstoffe |
AU2001276627A1 (en) | 2000-05-17 | 2001-11-26 | Labopharm Inc. | Drug containing polymeric micelles |
US6780428B2 (en) * | 2001-06-08 | 2004-08-24 | Labopharm, Inc. | Unimolecular polymeric micelles with an ionizable inner core |
US6939564B2 (en) * | 2001-06-08 | 2005-09-06 | Labopharm, Inc. | Water-soluble stabilized self-assembled polyelectrolytes |
GB0131112D0 (en) * | 2001-12-31 | 2002-02-13 | Univ London Pharmacy | Block copolymers |
ATE388758T1 (de) | 2002-10-21 | 2008-03-15 | Oreal | Verfahren zum auflösen lipophiler verbindungen, und kosmetische zusammensetzung. |
-
2003
- 2003-06-25 US US10/607,446 patent/US7094810B2/en not_active Expired - Lifetime
-
2004
- 2004-04-14 AT AT04727195T patent/ATE418970T1/de active
- 2004-04-14 EP EP04727195A patent/EP1638539B1/en not_active Expired - Lifetime
- 2004-04-14 MX MXPA05014017A patent/MXPA05014017A/es active IP Right Grant
- 2004-04-14 DE DE602004018772T patent/DE602004018772D1/de not_active Expired - Lifetime
- 2004-04-14 ES ES04727195T patent/ES2323701T3/es not_active Expired - Lifetime
- 2004-04-14 DK DK04727195T patent/DK1638539T3/da active
- 2004-04-14 SI SI200431088T patent/SI1638539T1/sl unknown
- 2004-04-14 AU AU2004248863A patent/AU2004248863B2/en not_active Ceased
- 2004-04-14 WO PCT/CA2004/000561 patent/WO2004112757A1/en active Application Filing
- 2004-04-14 CA CA2530736A patent/CA2530736C/en not_active Expired - Lifetime
- 2004-04-14 PT PT04727195T patent/PT1638539E/pt unknown
- 2004-04-14 BR BRPI0411872-3A patent/BRPI0411872A/pt not_active IP Right Cessation
- 2004-04-14 PL PL04727195T patent/PL1638539T3/pl unknown
- 2004-04-14 JP JP2006515571A patent/JP4619357B2/ja not_active Expired - Lifetime
-
2009
- 2009-03-31 CY CY20091100371T patent/CY1110264T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
US20040072784A1 (en) | 2004-04-15 |
CY1110264T1 (el) | 2015-01-14 |
DK1638539T3 (da) | 2009-05-04 |
AU2004248863A1 (en) | 2004-12-29 |
JP2007505029A (ja) | 2007-03-08 |
JP4619357B2 (ja) | 2011-01-26 |
ATE418970T1 (de) | 2009-01-15 |
CA2530736C (en) | 2013-07-02 |
CA2530736A1 (en) | 2004-12-29 |
AU2004248863B2 (en) | 2009-03-12 |
PL1638539T3 (pl) | 2009-10-30 |
WO2004112757A1 (en) | 2004-12-29 |
EP1638539B1 (en) | 2008-12-31 |
EP1638539A1 (en) | 2006-03-29 |
DE602004018772D1 (de) | 2009-02-12 |
ES2323701T3 (es) | 2009-07-23 |
PT1638539E (pt) | 2009-04-09 |
SI1638539T1 (sl) | 2009-10-31 |
MXPA05014017A (es) | 2007-01-31 |
US7094810B2 (en) | 2006-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0411872A (pt) | composição farmacêutica | |
CA2462606A1 (en) | Orally administered liquid compositions comprising guaifenesin and a polyoxyalkylene block copolymer | |
BR0111016A (pt) | Composições farmacêuticas de liberação sustentada para a administração parenteral de compostos hidrófilos biologicamente ativos | |
WO2003044076A8 (en) | Bioerodible poly(ortho esters) containing amine groups, and block copolymers containing them | |
ATE270544T1 (de) | Halbfeste arzneizubereitung enthaltend isotretinoin | |
BR0307893A (pt) | Formulação oftálmica com sistema de goma | |
BRPI0409185A (pt) | formulações veterinárias anti-helmìnticas tópicas | |
DE60134245D1 (de) | (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten | |
ATE468848T1 (de) | In organischen lösemitteln lösliche biologisch abbaubare poly (alkylenoxid)- poly (p-dioxanon) blockcopolymere sowie diese enthaltende zusammensetzung zur arzneistoffverabreichung | |
ATE313586T1 (de) | Mehrarmige blockcopolymere und pharmazeutische zusammensetzung | |
ATE363898T1 (de) | Mizellares arzneistoffverabreichungssystem für hydrophobe arzneistoffe | |
MA26888A1 (fr) | Solutions moleculaires dispersees hydrophiles de carvedilol | |
ATE355829T1 (de) | Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung | |
WO2005072343A3 (en) | Aqueous pharmaceutical compositions 2,6-diisopropylphenol (propofol) and their use | |
BR0305628A (pt) | Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso | |
BR0003987A (pt) | Composição laxativa | |
BR0213379A (pt) | Formulação resistente a derramamento de mascaramento de gosto | |
ATE549015T1 (de) | Pharmazeutische wirkstoffhaltige formulierung mit überzug | |
BR0110892A (pt) | Forma de administração farmacêutica para peptìdios, processos para preparação e uso dos mesmos | |
HRP20090022T3 (en) | Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superfinfections and fungal recurrences | |
MXPA04003540A (es) | Utilizacion de un copolimero para producir una forma galenica que contiene un peptido o proteina como agente activo. | |
BR0300698A (pt) | Compostos derivados de quinazolina, um processo para sua preparação e composições farmacêuticas contendo-os | |
UY27373A1 (es) | Formulaciones de interferón beta-humano | |
AU2001267561A1 (en) | Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined withspecific pharmaceutical active agents | |
ES2150404T3 (es) | Composiciones farmaceuticas de tizoxanida y nitozoxanida. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014. |